L'Horset F, Dauvois S, Heery D M, Cavaillès V, Parker M G
Molecular Endocrinology Laboratory, Imperial Cancer Research Fund, London, United Kingdom.
Mol Cell Biol. 1996 Nov;16(11):6029-36. doi: 10.1128/MCB.16.11.6029.
We have characterized two distinct binding sites, called site 1 and site 2, in the nuclear protein RIP-140 which interact with the ligand binding domain of the estrogen receptor both in solution and when the receptor is bound to DNA. Both sites are capable of independently interacting with other nuclear receptors, including the thyroid hormone and retinoic acid receptors, but they are not identical since the interaction with retinoid X receptor is mediated primarily by site 1. The interaction is enhanced by agonists but not by antagonists, and the in vitro binding activities to a number of mutant receptors correlate with their abilities to stimulate transcription in vivo. When RIP-140 is fused to heterologous DNA binding domains, it is able to stimulate the transcription of reporter genes in both yeast and mammalian cells. Thus, RIP-140 is likely to function as a bridging protein between receptors and the basal transcription machinery and thereby stimulate the transcription of target genes.
我们已对核蛋白RIP - 140中两个不同的结合位点进行了表征,分别称为位点1和位点2。在溶液中以及受体与DNA结合时,这两个位点均能与雌激素受体的配体结合域相互作用。两个位点都能够独立地与其他核受体相互作用,包括甲状腺激素受体和视黄酸受体,但它们并不相同,因为与视黄酸X受体的相互作用主要由位点1介导。激动剂可增强这种相互作用,而拮抗剂则不能,并且对多种突变受体的体外结合活性与其在体内刺激转录的能力相关。当RIP - 140与异源DNA结合域融合时,它能够在酵母和哺乳动物细胞中刺激报告基因的转录。因此,RIP - 140可能作为受体与基础转录机制之间的桥梁蛋白,从而刺激靶基因的转录。